Sunday, August 09, 2020 2:10:33 PM
I think its more important to see what Missling said about PDD. He has a legal obligation to be forthright.
In the prepared statement he read at the beginning (likely reviewed by a lawyer) he said "Finally, Parkinson's disease dementia top line results from the Phase II study are forthcoming and are expected to be announced during this fiscal quarter."
So we have a new word. What does 'forthcoming' mean. He was actually rather clear in this regard. To an analyst question he said "We said this quarter. And also, it will definitely be this quarter. I don't want to go in more specifics. We will report exactly when we have the data.". So we have a firm deadline of September 30, 2020. He seems adamant so maybe he has been told data is analyzed and a report will be with you by next week or end of August.
I think its fair to say that if Missling does not know the results that Clint does not know. In the Q and A Missling said "Right. We don't want to exclude anything. We just really take this as a very objective study to look at what happens in the study when treated with ANAVEX 2-73 versus control. And this is what we really look forward to seeing." and then in follow up said "Right. We just want to see a signal first, and that could be however it is, and that would be then -- certainly, we can move from there by sharing with the regulatory bodies and take it from there since it's a highly unmet need since now almost 80% of all Parkinson's patients develop dementia." When combined with "We will report exactly when we have the data", I take this to mean we have not yet seen the data.
Maybe it comes across different on the taped CC but the transcript statement is less confident than previous CC phrases. This might just be one of those poor communication things we have become accustomed to. Alternatively, the Statistical Plan (he has access to it, we don't) may have a hierarchical reporting -- if Top-line on the entire population is positive, they write report and send to Anavex, if not they do the stats on genetic subsets..if positive they report. If not they evaluate the secondary endpoints and then regardless of results send them to Anavex. He knows, like everyone else with a calendar, that we are now at 12 weeks post LPLV. Could delay, mean the statisticians are doing more pre-planned analysis before releasing to the company? Or maybe they just had one site that took 8 weeks to answer all the DCF queries and the top-line report is being written now
In the prepared statement he read at the beginning (likely reviewed by a lawyer) he said "Finally, Parkinson's disease dementia top line results from the Phase II study are forthcoming and are expected to be announced during this fiscal quarter."
So we have a new word. What does 'forthcoming' mean. He was actually rather clear in this regard. To an analyst question he said "We said this quarter. And also, it will definitely be this quarter. I don't want to go in more specifics. We will report exactly when we have the data.". So we have a firm deadline of September 30, 2020. He seems adamant so maybe he has been told data is analyzed and a report will be with you by next week or end of August.
I think its fair to say that if Missling does not know the results that Clint does not know. In the Q and A Missling said "Right. We don't want to exclude anything. We just really take this as a very objective study to look at what happens in the study when treated with ANAVEX 2-73 versus control. And this is what we really look forward to seeing." and then in follow up said "Right. We just want to see a signal first, and that could be however it is, and that would be then -- certainly, we can move from there by sharing with the regulatory bodies and take it from there since it's a highly unmet need since now almost 80% of all Parkinson's patients develop dementia." When combined with "We will report exactly when we have the data", I take this to mean we have not yet seen the data.
Maybe it comes across different on the taped CC but the transcript statement is less confident than previous CC phrases. This might just be one of those poor communication things we have become accustomed to. Alternatively, the Statistical Plan (he has access to it, we don't) may have a hierarchical reporting -- if Top-line on the entire population is positive, they write report and send to Anavex, if not they do the stats on genetic subsets..if positive they report. If not they evaluate the secondary endpoints and then regardless of results send them to Anavex. He knows, like everyone else with a calendar, that we are now at 12 weeks post LPLV. Could delay, mean the statisticians are doing more pre-planned analysis before releasing to the company? Or maybe they just had one site that took 8 weeks to answer all the DCF queries and the top-line report is being written now
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
